Study title: RM2003/00271/00 A double blind placebo controlled, parallel group study to evaluate two dose levels (5mg and 20mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12-17 yrs).
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Nervous System Diseases [C10] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: SUMATRIPTAN | |||||
| ATC code: N02CC01 | |||||
| Document link: Sumatriptan-SUM30045-ICHE3.pdf | |||||
| Document date: 2011-10-20 | |||||
| Study number: SUM30045 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |